A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
- 6 March 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 32 (5), 509-520
- https://doi.org/10.1007/s40273-014-0144-z
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A COMPARISON OF PHARMACEUTICAL REIMBURSEMENT AGENCIES' PROCESSES AND METHODS IN FRANCE AND SCOTLANDInternational Journal of Technology Assessment in Health Care, 2012
- New drugs and indications in 2010: inadequate assessment; patients at risk.2011
- Mediator scandal rocks French medical communityThe Lancet, 2011
- Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?Journal of Clinical Oncology, 2010
- Using Effectiveness and Cost-effectiveness to Make Drug Coverage DecisionsJama-Journal Of The American Medical Association, 2009
- Medicine reimbursement recommendations in Canada, Australia, and Scotland.2008
- Key principles for the improved conduct of health technology assessments for resource allocation decisionsInternational Journal of Technology Assessment in Health Care, 2008
- Single Technology Appraisals by NICEPharmacoEconomics, 2008
- Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence comparedHealth Policy, 2006
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004